Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flunisolide + salbutamol
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Flunisolide + salbutamol is a combination therapy used primarily for the treatment of asthma and other respiratory conditions. Flunisolide is a corticosteroid that reduces inflammation in the airways by preventing cells from releasing substances that cause asthma symptoms. Salbutamol (albuterol) is a beta-2 adrenergic receptor agonist that acts as a bronchodilator by relaxing the smooth muscles in the airways. This combination provides both immediate bronchodilation (from salbutamol) and addresses the underlying inflammation (with flunisolide).
- Brand names
- Aerobid + Proventil
- Other names
- flunisolide + albuterol
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on flunisolide + salbutamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flunisolide + salbutamol.